Will Novavax Make Investors a Fortune?
Small-cap vaccine manufacturers have been some of the most volatile stocks on the market. As demand for a COVID-19 vaccine continues to grow, many companies working on potential treatments have seen their shares double or triple since the start of 2020.
Novavax (NASDAQ: NVAX) is one of those companies -- its stock has almost quadrupled over the past three months. While this sounds fantastic, it's easy to forget that Novavax has been publicly listed on the NASDAQ since 1995. Considering that the stock used to trade as high as $300 per share and now trades for about $17, it's not surprising that some investors have lingering doubts and disappointments about this company.
However, Novavax also has quite a few things going for it now that it didn't have all those years ago. So what's the verdict on this small-cap biotech stock? Will it make investors a fortune with its upcoming candidates, or should you give this company a pass?
Source Fool.com
